NCT02785952 2025-05-21
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed